Bill would require Medicaid coverage of topical oxygen wound therapy in N.Y. | Epidermolysis bullosa treatment advances to Phase III trials | Bandage uses electrical currents to detect early-stage bedsores
March 25, 2015
Advanced Tissue SmartBrief
Your resource for current wound care information

Wound Care Update
Bill would require Medicaid coverage of topical oxygen wound therapy in N.Y.
The New York Senate and Assembly are considering legislation that would require the state's Medicaid program to again cover topical oxygen wound therapy. The state Senate's version of the bill was approved by the Senate Health Committee and sent to the Senate Finance Committee. The state Department of Health announced in December 2013 that coverage of TOWT by Medicaid would be discontinued. Brooklyn Daily Eagle (N.Y.) (3/19)
Share: LinkedInTwitterFacebookGoogle+Email
Epidermolysis bullosa treatment advances to Phase III trials
Scioderm announced the kickoff of a Phase III clinical trial for the company's epidermolysis bullosa treatment, which has shown promise in early studies. (3/19)
Share: LinkedInTwitterFacebookGoogle+Email
Research, Technology & Innovation
Bandage uses electrical currents to detect early-stage bedsores
A bandage under development at the University of California at Berkeley uses electrical currents to detect pressure ulcers as they are forming, before tissue damage extends to the skin's surface. The bandage could be used to spot-check suspect areas or incorporated into dressings to monitor wound healing, project leader Michel Maharbiz said. Business Standard (India)/Indo-Asian News Service (3/18)
Share: LinkedInTwitterFacebookGoogle+Email
Company raises funds for chronic venous insufficiency treatment
InterVene is developing a catheter-based therapy for chronic venous insufficiency that creates deep vein valves out of a patient's vein wall tissue. Boston Scientific, venture capital firms and angel investors have put money into the company, which raised $5.9 million in a recent funding round. (3/23)
Share: LinkedInTwitterFacebookGoogle+Email
Clinical trial compares 2 antibiotics for cellulitis
A clinical trial led by researchers at the Los Angeles Biomedical Research Institute has found that clindamycin and trimethoprim sulfamethoxazole had comparable effectiveness against uncomplicated cellulitis. The study included 500 adults and children; 80.3% of patients in the clindamycin group and 77.7% in the trimethoprim sulfamethoxazole group responded within seven to 10 days. (3/19)
Share: LinkedInTwitterFacebookGoogle+Email
Health Policy & Regulation
HHS releases draft rule for MU stage 3
HHS issued its proposed rule for stage 3 of meaningful use on Friday. The draft lays out the standards that providers will have to meet to receive Medicare and Medicaid EHR incentives and to avoid penalties. Stage 3 requirements include the use of five clinical decision support interventions. Feedback on the proposal will be accepted through May 29. HealthLeaders Media (3/23), (free registration) (3/20), Modern Healthcare (tiered subscription model) (3/20)
Share: LinkedInTwitterFacebookGoogle+Email
It does not matter how slowly you go as long as you do not stop."
-- Confucius,
philosopher and teacher
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about ADVTIS ->Meet Our People | Placing an Order | Why Use Advanced Tissue | Home
About Advanced Tissue
Advanced Tissue is a leading wound care supply company offering a comprehensive line of wound care products from virtually all manufacturers. We understand the many obstacles associated with effective wound treatment and use this insight to provide the efficient delivery of dressings to enable enhanced compliance and improved patient outcomes.
Contact Advanced Tissue
7003 Valley Ranch Drive
Little Rock, Arkansas 72223
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Kathryn Doherty

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information